Pulmonx Corporation (NASDAQ:LUNG) Receives $5.58 Consensus Price Target from Analysts

Shares of Pulmonx Corporation (NASDAQ:LUNG) have received an average rating of “Hold” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $5.5833.

LUNG has been the subject of a number of analyst reports. Canaccord Genuity Group cut their price objective on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Pulmonx from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently bought and sold shares of LUNG. R Squared Ltd purchased a new stake in Pulmonx in the first quarter valued at approximately $26,000. Cerity Partners LLC purchased a new stake in Pulmonx in the fourth quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new stake in Pulmonx in the third quarter valued at approximately $29,000. Opal Capital LLC purchased a new stake in Pulmonx in the fourth quarter valued at approximately $29,000. Finally, Regatta Capital Group LLC purchased a new stake in Pulmonx in the fourth quarter valued at approximately $30,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Pulmonx Stock Performance

NASDAQ:LUNG opened at $1.25 on Friday. The firm has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.63. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. The firm has a market cap of $52.80 million, a PE ratio of -0.96 and a beta of 0.28. Pulmonx has a 1-year low of $1.13 and a 1-year high of $3.88.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.33) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.33). The business had revenue of $20.59 million during the quarter, compared to analyst estimates of $20.43 million. Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. On average, equities analysts expect that Pulmonx will post -1.13 EPS for the current year.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.